In the last week, the market has stayed flat, but it's up 20% over the past year, with earnings forecast to grow by 17% annually. In such a landscape, identifying stocks that balance potential growth with financial stability is crucial. Penny stocks may be an older term, yet they remain relevant for investors seeking opportunities in smaller or newer companies; those backed by strong fundamentals can offer both value and growth potential.

Here we highlight a subset of our preferred stocks from the screener.

Anixa Biosciences (ANIX)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Anixa Biosciences, Inc. is a biotechnology company that develops therapies and vaccines targeting critical unmet needs in oncology, with a market cap of $116.70 million.

Operations: Anixa Biosciences, Inc. currently does not report any revenue segments.

Market Cap: $116.7M

Anixa Biosciences, Inc., with a market cap of US$116.70 million, is a pre-revenue biotechnology company focusing on oncology therapies and vaccines. Recent developments include the acceptance of an Australian patent for its breast cancer vaccine technology, which complements existing patents in major jurisdictions like the U.S., Europe, China, and Japan. The company's Phase 1 trial for this vaccine met primary endpoints and was well tolerated. Anixa's ongoing ovarian cancer CAR-T therapy trial has shown promising survival rates without dose-limiting toxicities. Despite being unprofitable, Anixa has reduced losses over five years and maintains sufficient cash runway for over a year without debt concerns.

Organogenesis Holdings (ORGO)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures, and commercializes products for advanced wound care and surgical and sports medicine markets in the United States, with a market cap of approximately $230.33 million.

Operations: The company generates revenue of $457.45 million from its regenerative medicine segment.

Market Cap: $230.33M

Organogenesis Holdings Inc., with a market cap of US$230.33 million, is navigating financial challenges as it remains unprofitable, reporting a significant net loss increase to US$96.27 million for Q2 2026. Despite being debt-free and having sufficient cash runway for over three years, the company faces declining revenue projections, expecting a decrease of 62% to 68% year-over-year. Recent developments include promising trial results for Affinity in wound care and FDA review acceptance for ReNu targeting knee osteoarthritis pain. The company is trading below its estimated fair value but has initiated a $75 million follow-on equity offering to bolster finances.

Kaltura (KLTR)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Kaltura, Inc. offers a range of software-as-a-service and platform-as-a-service products globally, with a market cap of $254.76 million.

Operations: The company's revenue is derived from two main segments: Media & Telecom, which generated $43.20 million, and Enterprise, Education and Technology, contributing $137.73 million.

Market Cap: $254.76M

Kaltura, Inc., with a market cap of US$254.76 million, is navigating its unprofitable status while showing progress in reducing losses by 32.5% annually over the past five years. The company's cash reserves exceed its debt, providing a runway for more than three years despite short-term liabilities exceeding assets. Recent product innovations include real-time emotional intelligence for Agentic Avatars and successful live streaming during the 2026 FIFA World Cup, demonstrating technological advancement and operational scalability. Revenue guidance for 2026 suggests growth to between US$183 million and US$185 million, although earnings are forecast to decline by 9.2% annually over the next three years.

Where To Now?

• Unlock our comprehensive list of 321 US Penny Stocks by clicking here.
• Looking For Alternative Opportunities? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.